201 related articles for article (PubMed ID: 31956368)
1. Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy.
Ishii N; Nishikawa H; Iwata Y; Enomoto H; Tanaka H; Katakami N; Nishimura T; Iijima H; Nishiguchi S
J Cancer; 2020; 11(5):1223-1230. PubMed ID: 31956368
[No Abstract] [Full Text] [Related]
2. The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma.
Hall WA; Colbert LE; Nickleach D; Switchenko J; Liu Y; Gillespie T; Lipscomb J; Hardy C; Kooby DA; Prabhu RS; Kauh J; Landry JC
J Gastrointest Oncol; 2014 Apr; 5(2):77-85. PubMed ID: 24772334
[TBL] [Abstract][Full Text] [Related]
3. Score for predicting overall survival in pancreatic adenocarcinoma patients with positive lymph nodes after surgery: a novel nomogram-based risk assessment.
Jin L; Zou Y; Ruan S; Han H; Zhang Y; Chen Z; Jin H; Shi N
Gland Surg; 2021 Feb; 10(2):529-540. PubMed ID: 33708536
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.
Shin K; Jung EK; Park SJ; Jeong S; Kim IH; Lee MA
World J Gastrointest Oncol; 2021 Aug; 13(8):915-928. PubMed ID: 34457195
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
6. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.
Fu N; Qin K; Li J; Jin J; Jiang Y; Deng X; Shen B
Cancer Med; 2022 Sep; 11(18):3397-3406. PubMed ID: 35434972
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.
Huang L; Balavarca Y; van der Geest L; Lemmens V; Van Eycken L; De Schutter H; Johannesen TB; Zadnik V; Primic-Žakelj M; Mägi M; Grützmann R; Besselink MG; Schrotz-King P; Brenner H; Jansen L
BMC Med; 2019 Mar; 17(1):66. PubMed ID: 30905320
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
10. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score.
Hank T; Sandini M; Ferrone CR; Ryan DP; Mino-Kenudson M; Qadan M; Wo JY; Klaiber U; Weekes CD; Weniger M; Hinz U; Harrison JM; Heckler M; Warshaw AL; Hong TS; Hackert T; Clark JW; Büchler MW; Lillemoe KD; Strobel O; Castillo CF
Ann Surg; 2022 Feb; 275(2):391-397. PubMed ID: 32649455
[TBL] [Abstract][Full Text] [Related]
11. Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy.
Ishii N; Iwata Y; Nishikawa H; Enomoto H; Aizawa N; Ishii A; Miyamoto Y; Yuri Y; Hasegawa K; Nakano C; Nishimura T; Yoh K; Sakai Y; Ikeda N; Takashima T; Takata R; Iijima H; Nishiguchi S
Oncol Lett; 2017 Nov; 14(5):6059-6065. PubMed ID: 29113246
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis.
Mattiucci GC; Morganti AG; Cellini F; Buwenge M; Casadei R; Farioli A; Alfieri S; Arcelli A; Bertini F; Calvo FA; Cammelli S; Fuccio L; Giaccherini L; Guido A; Herman JM; Macchia G; Maidment BW; Miller RC; Minni F; Regine WF; Reni M; Partelli S; Falconi M; Valentini V
Transl Oncol; 2019 Jan; 12(1):1-7. PubMed ID: 30237099
[TBL] [Abstract][Full Text] [Related]
13. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
14. Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection.
Chiang KC; Yeh CN; Lee WC; Jan YY; Hwang TL
World J Gastroenterol; 2009 Sep; 15(34):4305-10. PubMed ID: 19750574
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?
Formentini A; Sander S; Denzer S; Straeter J; Henne-Bruns D; Kornmann M
Int J Colorectal Dis; 2007 Jan; 22(1):49-55. PubMed ID: 16538493
[TBL] [Abstract][Full Text] [Related]
16. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
[TBL] [Abstract][Full Text] [Related]
17. Survival and prognostic factors of unresectable pancreatic cancer.
Park JK; Yoon YB; Kim YT; Ryu JK; Yoon WJ; Lee SH
J Clin Gastroenterol; 2008 Jan; 42(1):86-91. PubMed ID: 18097296
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.
Asama H; Suzuki R; Takagi T; Sugimoto M; Konno N; Watanabe K; Nakamura J; Kikuchi H; Takasumi M; Sato Y; Irie H; Hikichi T; Ohira H
Mol Clin Oncol; 2018 Oct; 9(4):408-414. PubMed ID: 30233794
[TBL] [Abstract][Full Text] [Related]
19. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
20. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
Colbert LE; Fisher SB; Hardy CW; Hall WA; Saka B; Shelton JW; Petrova AV; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Curran WJ; Landry JC; Maithel SK; Yu DS
Cancer; 2013 Sep; 119(17):3148-55. PubMed ID: 23720157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
